Candriam Luxembourg S.C.A. decreased its stake in Aetna Inc. (NYSE:AET) by 51.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,867 shares of the company’s stock after selling 31,874 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Aetna were worth $4,535,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Aetna by 3,374.9% in the first quarter. BlackRock Inc. now owns 30,712,219 shares of the company’s stock valued at $3,917,344,000 after buying an additional 29,828,390 shares in the last quarter. Vanguard Group Inc. boosted its position in Aetna by 3.8% in the first quarter. Vanguard Group Inc. now owns 23,117,526 shares of the company’s stock valued at $2,948,640,000 after buying an additional 838,578 shares in the last quarter. FMR LLC boosted its position in Aetna by 2.2% in the first quarter. FMR LLC now owns 7,903,233 shares of the company’s stock valued at $1,008,059,000 after buying an additional 167,261 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Aetna by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 4,378,982 shares of the company’s stock valued at $558,540,000 after buying an additional 165,278 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Aetna by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 3,962,514 shares of the company’s stock valued at $505,399,000 after buying an additional 21,953 shares in the last quarter. 91.69% of the stock is currently owned by hedge funds and other institutional investors.

Aetna Inc. (AET) traded down 0.87% during mid-day trading on Friday, hitting $154.45. 1,781,161 shares of the stock were exchanged. The stock has a market capitalization of $51.29 billion, a PE ratio of 34.28 and a beta of 0.54. The company has a 50-day moving average of $154.81 and a 200-day moving average of $140.38. Aetna Inc. has a 52 week low of $104.59 and a 52 week high of $161.69.

Aetna (NYSE:AET) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $2.34 by $1.08. Aetna had a net margin of 2.52% and a return on equity of 20.52%. The business had revenue of $15.52 billion during the quarter, compared to analysts’ expectations of $15.34 billion. During the same period last year, the company posted $2.21 EPS. The business’s revenue was down 2.7% on a year-over-year basis. On average, equities analysts predict that Aetna Inc. will post $9.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/19/aetna-inc-nyseaet-shares-sold-by-candriam-luxembourg-s-c-a-updated.html.

Several equities research analysts have recently issued reports on AET shares. Stifel Nicolaus restated a “buy” rating and set a $150.00 price target (up previously from $130.00) on shares of Aetna in a research note on Wednesday, May 3rd. Royal Bank Of Canada raised their price target on shares of Aetna from $147.00 to $162.00 and gave the stock an “outperform” rating in a research note on Friday, June 9th. BidaskClub lowered shares of Aetna from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Deutsche Bank AG raised their price target on shares of Aetna from $157.00 to $163.00 and gave the stock a “hold” rating in a research note on Monday, August 7th. Finally, UBS AG reiterated a “buy” rating and issued a $160.00 price objective (up from $147.00) on shares of Aetna in a research note on Wednesday, May 17th. Seven research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Aetna currently has a consensus rating of “Buy” and a consensus target price of $157.99.

In other Aetna news, EVP Margaret M. Mccarthy sold 27,028 shares of Aetna stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $149.23, for a total value of $4,033,388.44. Following the completion of the transaction, the executive vice president now directly owns 33,563 shares of the company’s stock, valued at approximately $5,008,606.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.90% of the company’s stock.

Aetna Company Profile

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Institutional Ownership by Quarter for Aetna (NYSE:AET)

Receive News & Stock Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related stocks with our FREE daily email newsletter.